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1. Introduction  
Gene delivery, transfection, cytotoxicity, and many other factors influence the ability of gene 
therapy to treat cancer. In addition, as with pharmacologic agents, longer exposure to higher 
concentrations of gene products should intensify their effects (Wada et al., 2007). Cytotoxic 
gene products, such as FasL and TRAIL, may remain in tissues after the death of the 
transfected cells, and they are known to induce apoptosis in both transfected cells and 
neighbouring cells (Hyer et al., 2003; Kagawa et al., 2001). They have been examined for use 
in cancer gene therapy and its effects have been examined in vitro and in vivo (Elojeimy et 
al., 2006; Griffith et al., 2009). FasL delivered via a viral vector can reduce tumour size and 
improve prognosis in an explanted tumour model. 
 
 
a. Immunohistochemical staining for Del1 in a 14.5 dpc (days post coitum) mouse embryo. Sections 
were stained with anti-Del1 antibody, followed by an alkaline phosphatase-conjugated secondary 
antibody and naphthol red as a colorimetric substrate. Immunoreactive protein appears red. Staining 
for Del1 appeared in the subendocardial region. b. The domain structure of Del1 protein. The RGD 
sequence in the second EGF motif is indicated. 
Fig. 1. Expression and structure of Del1 protein 
Currently, multiple injections with a gene therapeutic agent are needed because it is 
unlikely for a single injection to eliminate a cancer. Therefore, gene therapeutic agents need 
to be not only safe but inexpensive. Non-viral vectors represent a possible safe and 
inexpensive way of delivering genes for gene therapy (Lungwitz et al., 2005). However, the 
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gene transfer efficiency of non-viral vectors remains low. New non-viral vectors that are 
non-carcinogenic, non-immunogenic, and highly efficient are currently being developed. 
Here, we discuss the use of non-viral vectors encoding Del1 in cancer gene therapy. Del1 is 
an extracellular matrix (ECM) protein expressed by embryonic endothelial cells and 
hypertrophic chondrocytes (Fig. 1a) (Hidai et al., 1998). We examined the biological 
functions of Del1 domains by generating non-viral vectors encoding fragments of the Del1 
gene. 
2. Del1 and its application in cancer gene therapy 
Del1 is a 480-amino acid protein made up of five regions, including three epidermal growth 
factor (EGF) repeats (E1-3) at its N-terminus and two discoidin domains (C1 and C2) at its 
C-terminus (Fig. 1b). The C1 domain is essential for the deposition of Del1 in the ECM, and 
E3 enhances the ECM deposition mediated by C1 (Hidai et al., 2007). Proteins fused to the 
E3 and C1 domains are deposited in the ECM, where they accumulate. The E3 domain can 
also increase the endocytosis of transfected genes, and at high concentrations, E3 induces 
apoptosis (Kitano et al., 2008, 2010). We therefore examined the possible application of Del1 
in cancer gene therapy by transfecting a squamous cell carcinoma line with cDNA encoding 
a FasL-E3C1 fusion protein. This protein was deposited in ECM, increased apoptosis, and 
enhanced the efficiency of a following second transfection in vitro. 
2.1 E3 enhances the efficiency of gene transfection 
Although viral vectors are highly efficient for gene transfer, they can be carcinogenic and 
immunogenic (Check, 2002). They also require more time and are more expensive than non-
viral vectors. However, non-viral vectors are less efficient for gene transfer. Various 
methods have been made to improve the efficiency of non-viral vectors. For example, novel 
chemical transfection reagents have been developed to improve extracellular binding. Also, 
vectors have been modified with chemicals, growth factor peptides, extracellular matrix 
proteins, and viral proteins to improve uptake via receptor-mediated endocytosis (Al-Taei et 
al., 2006; Kikuchi et al., 1996; Nam et al., 2009; Oba et al., 2007). 
Although the characteristics of the transfection reagents are important, differences between 
cell types are a more important determinant of transfection efficiency; some cells are always 
more easily transfected than others (Von Gersdorff et al., 2006). In this regard, the biological 
state of a given cell type, such as which endocytic pathways are functional in the cell prior to 
treatment, may be an important factor in endocytosis-mediated gene transfer. Molecules 
that initiate and enhance endocytosis are needed to improve endocytosis as a method for 
delivering exogenous molecules. 
Del1 protein is one such a factor that increases the efficiency of transfection in vitro and in 
vivo (Kitano et al., 2008). We have found that conditioned medium containing Del1 increases 
LacZ gene transfection using several non-viral gene transfer systems, including lipoplex and 
polyplex systems. Experiments using deletion mutants and fragments of Del1 have shown 
that domain E3 of Del1 mediates the enhancement of gene transfer. Incubation of culture 
cells with as low as 16 pM of recombinant E3 is sufficient to enhance transfection, and 1 nM 
recombinant E3 enhances the transfection 12-fold. This effect of E3 was observed in every 
cell type tested. E3 enhanced transfection even when it was administrated to the cell culture 
medium before transfection. The effects of Del1 on gene transfer are inhibited by both of 
nystatin, an inhibitor of caveolin-dependent endocytosis, and chlorpromazine, an inhibitor 
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of clathrin-dependent endocytosis. Furthermore, the addition of E3 to cell culture medium 




a. Confluent COS-7 cells were cultured with 1-µm diameter fluorescent beads (Invitrogen, Carlsbad, 
CA) and 1 nM of an alkaline phosphatase (AP)-E3 fusion protein (left side of panel a) for 1 h, washed 
with PBS, and visualized by fluorescence microscopy. AP protein was used as a negative control (right 
side of panel a). b. Fluorescence intensity evaluated using image analysis software (AquaCosmos, 
Hamamatsu photonics, Hamamatsu, Japan). Fluorescence was normalized by the control samples. 
Results represent means ± SEM (n=6). The results show that recombinant E3 increases phagocytosis. 
Fig. 2. Effect of recombinant E3 on phagocytosis 
 
 
Fig. 3. Effect of recombinant E3 on gene transfer in vivo 
The effects of Del1 on gene transfer were observed in vivo. We found two-fold higher serum 
alkaline phosphatase activity following transfection with a heat-stable alkaline phosphatase 
(AP) cDNA in mice over-expressing Del1 compared wild-type littermates (Fig. 3). These 
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results suggest that the E3 fragment of Del1 in ECM can be used as a general enhancer of 
non-viral gene transfer. 
Del1 over-expressing mice (TG) and wild-type mice (WT) were intravenously injected with a 
cDNA encoding AP using jet-PEI (Polyplus-transfection, San Marco, CA, USA). Mice 
injected with an empty vector were used as negative controls. After 24 h, serum AP activity 
was measured. AP activities were normalized by the AP activity of wild-type mice. Results 
represent means ± SEM (n=6). N.S., not significant. These results revealed that Del1 
increased the susceptibility to gene transfer in vivo. 
2.2 E3 induces apoptosis 
Del1 is present in branchless cavities, such as the heart and umbilical veins, as well as in 
avascular tissue with hypertrophic chondrocytes in developing embryos (Hidai et al., 1998). 
In transgenic mice, constitutive expression of Del1 decreases the total volume of the vascular 
bed (Hidai et al., 2005). These findings suggest that Del1 is inhibits angiogenesis activity. 
However, some evidence suggests that Del1 promotes angiogenesis. Zhong et al. reported 
that Del1 can stimulate angiogenesis in animal models of ischemia (Zhong et al., 2003). 
Additionally, Del1 can accelerate tumor growth by enhancing vascular formation (Aoka et 
al., 2002). Del1 has seemed to have ambiguous characteristics. 
We have found that Del1 induces cell death in vitro (Fig. 4) (Kitano et al., 2010). Treatment of 
cells with Del1 results in chromatin condensation and DNA laddering, suggesting 
apoptosis. Experiments using TUNEL and annexin V staining also suggest that Del1 induces 
apoptosis. The apoptosis-inducing activity of Del1 is localized in E3. As little as 25 pM 
recombinant E3 is sufficient to induce apoptosis, and we have found that E3 induces 
apoptosis in all adhesive cell types examined. Because of this ability to induce cell death, the 
E3 domain of Del1 might be useful for cancer gene therapy. 
 
 
COS-7 cells were transfected with Del1 cDNA (a) or an empty vector. (b). After 24 h, fragmented DNA 
was detected with a TACS2 TdT-blue label in situ apoptosis detection kit (Trevigen, Gaithersburg, MD, 
USA). Cells were counterstained with Nuclear Fast Red. Bar , 20 µm. 
Fig. 4. In situ detection of DNA fragmentation induced by a recombinant E3 
The C1 domain of Del1 also mediates apoptosis. Hanayama et al. reported that the C1 
domain binds to phosphatidylserine (PS), a component of the plasma membrane 
(Hanayama et al., 2004). In healthy cells, PS is maintained on the inner leaflet of the plasma 
membrane lipid bilayer. However, in apoptotic cells, PS is present in the outer leaflet. Del1 
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may link phagocytes with apoptotic cells via the integrin-binding RGD sequence in the E2 
domain and the PS-binding C1 domain, which can bind to apoptotic cells. Thus, Del1 can 
both initiate apoptosis and enhance the elimination of apoptotic cells. 
2.3 C1 as a deposition domain 
The ECM is a critical factor in morphogenesis (Fujiwara et al., 2011; Sakai et al., 2003). 
Because the organization of the ECM directly influences the structure of tissues and organs, 
determining how ECM organization is regulated can help clarify the process of 
morphogenesis. We therefore investigated how Del1 is assembled in the ECM using an AP-
Del1 fusion protein. We found that the fusion protein is secreted from cells and deposited in 
the ECM (Fig. 5). 
 
 
Fig. 5. Del1 deposition domain can immobilize AP protein 
CHO cells were cultured and transfected with cDNA of an AP-Del1 fusion protein. Cells 
were removed from tissue culture plates with EDTA and the ECM remaining was collected 
with a cell scraper, followed by centrifugation. Collected ECM pellets were incubated with 
p-nitrophenyl phosphate in microcentrifuge tubes. The ECM pellet on the left was collected 
from wild-type cells, the pellet in the middle from cells transfected with a cDNA encoding 
AP, and the pellet on the right from cells transfected with cDNA encoding the AP-Del1 
fusion protein. The pellet on the right was stained purple indicating that the AP-Del1 fusion 
protein was present in the ECM. 
Using various Del1 deletion mutants, we have found that the C-terminus of the C1 
domain, which contains a lectin-like structure, mediates ECM deposition (Hidai et al., 
2007). The efficiency of deposition is influences by the presence of other domains in Del1. 
A fragment containing E3 and C1 (E3C1) had the highest level of ECM deposition, with 
approximately 70% of the secreted AP fusion protein deposited in the ECM. In contrast, 
fragments containing C2, which is highly homologous to C1, were present at much lower 
levels in the ECM. The E3C1 fragment was deposited in the ECM by all cell types 
examined, although the efficiency varied. Digestion of the ECM with bovine testis 
hyaluronidase released Del1 from ECM, suggesting that glycosaminoglycans are involved 
in the deposition of Del1. 
In vivo gene transfer experiments in mice showed that the deposition domain of Del1 
dramatically alters the distribution of exogenous proteins. The AP activity in liver was 8 times 
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higher and the serum activity 30 times lower in mice injected intravenously with a cDNA 
encoding an AP-E3C1 fusion protein than in mice injected with a cDNA encoding AP alone.  
In addition to AP protein, the E3C1 sequence of Del1 can immobilize several proteins, 
including yellow fluorescent protein (YFP) (Fig. 6). Therefore, the E3C1 sequence should be 
a powerful tool for targeting therapeutic proteins to target tissues and thereby increasing the 
efficacy and decreasing side-effects.  
 
 
a COS-7 cells were transfected with cDNA encoding YFP fused with E3C1. After 48 h, cells were 
removed with EDTA and observed by fluorescence microscope. Bar, 10 µm. Specific staining of the 
ECM was observed. b. Fluorescence intensity in the ECM. Values were corrected by the fluorescence 
from unconditioned ECM. Values were normalized to the fluorescence from cells expressing cDNA 
encoding YFP alone. Results represent mean ± SEM (n=6). The data indicate that E3C1 can immobilize 
YFP protein in ECM. 
Fig. 6. YFP-E3C1 fusion stains the ECM 
To examine whether the E3C1 domain interferes with the function of fused enzymes, we 
fused it to 3α-hydorxysteroid dehydrogenase and expressed it in the prostatic cancer-
derived, androgen-dependent cell line LNCap (Hidai et al., 2009). The 3α-hydorxysteroid 
dehydrogenase-E3C1 fusion protein was localized in the ECM and metabolized 
dihydrotestosterone in the medium, inhibiting cell growth. Thus, the E3C1 domain can 
target proteins to the ECM without interfering with their function. 
2.4 Potential of a FasL-E3C1 fusion protein in cancer gene therapy 
We next considered fusing the E3C1 domain to FasL, a cytotoxic protein that has been 
studied for cancer gene therapy. A FasL-E3C1 fusion protein was deposited and 
concentrated in the ECM and enhanced the efficiency of subsequent transfections with the 
same plasmid (Fig. 7). 
SCCKN oral squamous cell carcinoma cells (Urade et al., 1992) were transfected with a non-
viral vector encoding a FasL-E3C1 fusion protein or encoding FasL alone (control). Three 
days later, the cells were transfected with a cDNA encoding AP. E3C1 was expected to 
target FasL to the ECM, increase cytotoxicity, and increase the efficiency of the secondary 
transfection with AP. 
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Fig. 7. Scheme describing repetitive gene therapy using a FasL-E3C1 fusion protein.  
2.4.1 The E3C1 sequence of Del1 targets FasL to the ECM 
2.4.1.1 Materials and methods 
Cell culture 
CHO cells were purchased from ATCC and grown in α-minimum essential medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen). The 
human oral squamous cell carcinoma cell line, SCCKN, a gift from Dr. Hayashido, 
Hiroshima university, was grown in RD medium (45% Dulbecco's modified Eagle's medium 
[Invitrogen], 45% RPMI 1640 medium (Invitrogen), and 10% fetal bovine serum. Cells were 
cultured in 5% CO2 at 37°C. 
DNA constructs 
Mouse FasL cDNA was a gift of Dr. Tagawa, Chiba cancer center. Mouse Del1 cDNA in 
pcDNA3 (Invitrogen, Carlsbad, CA) was a gift from Dr. Quertermous, Stanford university. 
First, a cDNA fragment encoding the mouse FasL gene was amplified by reverse 
transcriptase-PCR using the forward primer 5’- 
TACCGAGCTCGGATCCATGCAGCAGCCCATGAATTAC and the reverse primer 5’- 
GGCACTGTGCTGGATATCAAGCTTATACAAGCCGAA and then cloned into pcDNA3D 
(Invitrogen), resulting in pFasL. Next, a fragment encoding the E3 and D1 sequence (E3D1, 
amino acids 122–316 of mouse Del1) was amplified with the forward primer 5’-
TGTGAAGCTGAGCCTTGCAGAATGGCCGGA and the reverse primer 5’- 
ACAGCCTGAGAGCTCACAGCCAAGAAGTT and cloned into the 3’-end of the FasL gene 
in pFasL, resulting in pFasL-E3D1. The recombinant proteins expressed by these constructs 
also had a V5 epitope tag at their C-terminal ends. 
Immunoblotting 
Immunoblotting was used to determine whether E3C1 can target FasL protein to the ECM. 
CHO cells were used for the experiment because they are more efficiently transfected than 
SCCKN cells. CHO cells was cultured in 60-mm tissue culture plates and transfected with 
pFasL-E3D1, pFasL, or a empty vector using jet-PEI (PolyPlus-transfection; San Marcos, 
CA). Six hours later, the medium was replaced with 3 ml of fresh medium. After 72 h, cells 
were harvested by incubation with 10 mM EDTA and then solubilized with SDS-sample 
buffer. Next, the remaining ECM was fixed with 1 ml of 10% trichloroacetic acid in PBS 
(Wako, Osaka, Japan) and harvested with a cell scraper. One-fourth of the protein from the 
samples was analyzed by SDS-polyacrylamide gel electrophoresis, after which protein was 
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transferred to a poluvinylidene difluoride membrane (ATTO, Tokyo, Japan). After blocking 
and incubation with anti-V5 antibody (Invitrogen), anti-laminin antibody (Sigma, Saint 
Louis, MO), or anti-tubulin antibody (Oncogene, San Diego, CA), and HRP conjugated 
secondary antibody (Cell signaling technology, Denvers, MA). an ECL advance western 
blotting detection kit (Amersham, Piscataway, NJ) was used to detect immunoreactive 
protein. 
2.4.1.2 Results 
Immunoblotting of cell lysate showed that the recombinant FasL and FasL-E3C1 fusion 
proteins had the expected sizes (Fig. 8a). Immunoblotting of conditioned ECM remaining 
after cell removal showed that FasL-E3C1 fusion protein but not FasL was present in the 
ECM (Fig. 8b). 
 
 
Fig. 8. Immunoblotting 
Immunoblotting of cell lysate (a) and ECM (b) from CHO cells transfected with empty 
vector, pFasL, or pFasL-E3C1. Immunoblotting for tubulin and laminin was used to confirm 
equal loading. 
2.4.2 The E3C1 fragment of Del1 improved the effects of FasL 
2.4.2.1 Materials and methods 
Induction of apoptosis by FasL fusion proteins 
SCCKN cells were plated on a 24-weel plate at 30% confluency. After 1 or 4 days, cells were 
transfected with an empty vector, pFasL, or pFasL-E3C1. Cells were co-transfected with 
pAP-tag4 (GenHunter, Nashville, TN) as a control for transfection efficiency. After 48 h, cell 
death was analyzed by measuring lactate dehydrogenase (LDH) in the cell medium using a 
LDH cytotoxicity detection kit (Takara) according to the manufacturer’s protocol (Decker 
and Lohmann-Matthes, 1988; Legrand et al., 1992). Percent cell death was calculated as 100% 
x [(LDH activity for the test condition – LDH activity for the negative control)/LDH activity 
in cells treated with 1% Triton X-100 (positive control)]. LDH activity was normalized to the 
heat stable AP activity, which was measured as follows. Conditioned medium (20 µl/well) 
was added to a 96-well plate, heated at 65ºC for 30 min to inactivate endogenous AP 
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activity, and mixed with 200 µl/well of 1 mg/ml p-nitrophenyl phosphate (Sigma, St Louis, 
MO) in 1 mM MgCl2 and 1 M diethanolamine, pH 9.8. The absorbance at 405 nm was 
measured after 30 to 60 min. 
2.4.2.2 Results 
In a first set of experiments, cells were transfected with plasmids 1 day after plating (Fig. 9a). 
In this experiment, expression of the FasL-E3C1 fusion protein was as cytotoxic as FasL. 
Because the deposition activity of Del1 varies between cells, possibly because of the 
composition and amount of ECM, we repeated the experiment with transfection 4 days after 
plating to allow them to produce sufficient ECM (Fig. 9b). Under these conditions, transfection 
with pFasL-E3C1 was twice as effective as transfection with pFasL at inducing cell death. 
 
 
Fig. 9. Effect of E3C1 on the cytotoxicity of FasL 
KN cells were transfected 1 (a) or 4 (b) days after plating with an empty vector, pFasL, or 
pFasL-E3C1. Results represent means ± SEM (n=8). N.S., not significant. Asterisk, P<0.01. 
2.4.3 The E3C1 fragment of Del1 enhances the efficiency of a following transfection 
2.4.3.1 Materials and methods 
Evaluation of the effects of FasL-E3C1 on the efficiency of a second gene transfer 
SCCKN cells were cultured at 30% confluency in 96-well plates for 4 days. The cells were 
transfected with 1 μg of pFasL, pFasL-E3C1, or empty vector (negative control) using jet-
PEI. After the cells were cultured for 72 h, the cells that survived the first transfection were 
transfected with pAPtag-4. Next, the cells were cultured for 24 h before analysis. The AP 
activity in medium was measured as described above. To count the number of cells, cells 
were harvested with trypsin EDTA, stained with Trypan blue, and counted using a counting 
chamber. The AP activity was calculated as the total AP activity in medium/cell numbers. 
2.4.3.2 Results 
The efficiency of the second transfection was evaluated by measuring the secreted AP 
activity per cells (Fig. 10). Efficiency increased in the following order: empty vector < pFasL 
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< pFasL-E3C1. Because cells transfected with empty vector during the first transfection were 
cultured for 8 days without significant cell death, they may have been too dense to allow for 
an efficient second transfection, which could explain the higher efficiency of secondary 
transfection in the pFasL-transfected cells than in the control cells. 
 
 
Fig. 10. Effect of E3C1 on secondary transfection with AP 
Results represent mean ± SEM (n=8). N.S., not significant. Asterisk, P<0.01. 
2.5 Discussion 
Expression of Del1 is cell- and tissue-specific. As some reports suggest that Del1 promotes 
angiogenesis, whereas other reports suggest that it inhibits it, Del1 may be bifunctional. 
Furthermore, the E3 and C1 domains of Del1 have distinct functions and can act on a variety 
of cells, and they might be useful as fusion partners to enhance gene therapy using FasL or 
other proteins. 
Neck and esophageal cancer can cause obstruction. Although they can be treated using 
radiation therapy, its use is limited by the total dosage. As an alternative treatment, we 
designed a fusion protein of FasL and E3C1 to allow multiple rounds of cancer gene therapy 
with non-viral vectors. Further study of this fusion protein in the treatment of cancer needs 
is warranted and should be explored in vivo using an explanted tumor model. 
3. Conclusion 
The E3C1 fragment of Del1 can substantially improve the efficiency of cancer gene therapy 
using FasL. 
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